The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Review article: safety of infliximab in clinical trials
Open accessAbstract
Infliximab, a chimeric monoclonal antibody to tumour necrosis factor‐alpha, contains murine protein elements and targets the immune system, raising concerns about the potential for immune sensitization and immuno‐suppressive sequelae. However, long‐standing inflammatory disease with high activity and chronic immunosuppressant therapy can also predispose patients to immunosuppressive sequelae. Patients with Crohn’s disease, rheumatoid arthritis and other indications received single or multiple doses of infliximab and their condition was followed for up to 3 years. Adverse events, most frequently headache, nausea, and upper respiratory tract infection, were generally mild and occurred in 76% of infliximab‐treated patients vs. 57% of placebo‐treated recipients. Human antichimeric antibodies developed in 13% of patients, increasing the potential for subsequent infusion reactions. Antibodies to double‐stranded DNA developed in a small percentage of patients. Other antinuclear antibodies characteristic of serum lupus erythematosus were not found; no patient developed a true lupus syndrome and no other autoimmune disorders were reported. Infliximab is not associated with typical immunosuppressive sequelae, such as infections and malignancy, or with autoimmune disorders. Infliximab therapy was well tolerated, serious adverse events were infrequent, successfully managed with medication and without sequelae, and overall mortality was within the expected incidence for this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citation
Cited by
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement
Baughman, R. P., Drent, M., Kavuru, M., Judson, M. A., Costabel, U., du Bois, R., Albera, C., Brutsche, M., Davis, G., Donohue, J. F., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-402oc · Cited by 714
Ledingham, J., Deighton, C., & on behalf of the British Society for Rheumatology Standards, G. A. A. W. G. (2005) · Rheumatology · doi:10.1093/rheumatology/keh464 · Cited by 331
Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy
Tsiodras, S., Samonis, G., Boumpas, D. T., & Kontoyiannis, D. P. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60839-2 · Cited by 331
Vermeire, S., Noman, M., Van Assche, G., Baert, F., Van Steen, K., Esters, N., Joossens, S., Bossuyt, X., & Rutgeerts, P. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00701-7 · Cited by 327
Metadata
- Authors
- Hanauer, S. B.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1999-09
- Volume
- 13
- Issue
- s4
- Pages
- 16-22
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1995177703
- Cited by
- 172
- References
- 1
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review article: safety of infliximab in clinical trials. https://app.cochat.ai/papers/10.1046/j.1365-2036.1999.00027.x
- The paper
- Hanauer, S. B. (1999). Review article: safety of infliximab in clinical trials. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.1999.00027.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.